Unlabelled: BASICS: Drug treatment of the risk factor hypertension has not led to the expected reduction in morbidity and mortality of coronary arterial disease. A negative effect of antihypertensive drugs on the lipid metabolism is under discussion as a possible cause.
Main Topics: Both the commonly employed thiazide diuretics and chlorthalidone and the loop diuretics furosemide, piretanide and xipamide lead, to varying extents, to an increase in total and LDL cholesterol as well as triglycerides in subjects with normal metabolism. In addition, some diuretics lower the levels of protective HDL cholesterol. These side effects can be avoided--at least in part--by a combination with such drugs as prazosin, pindolol or captopril, which have a favorable effect on metabolism.
Conclusion: It is recommended to carefully monitor serum Lipoproteins during diuretic treatment so that possible adverse changes may be counteracted by appropriate measures.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparison of Robot-assisted Laparoscopic Extravesical Ureteral Reimplantation for Primary Vesicoureteral Reflux in Infants Under One Year of Age and Older Children.
J Pediatr Surg
December 2024
Department of Pediatric Urology, Department of Senior Pediatrics, The Seventh Medical Centre, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China; Medical School of Chinese People's Liberation Army (PLA), Beijing, China. Electronic address:
Purpose: To assess the surgical outcomes of Robot-Assisted Laparoscopic Extravesical Ureteral Reimplantation (RALUR-EV) in infants under one year of age with primary vesicoureteral reflux (VUR) as compared to older children.
Materials And Methods: A retrospective analysis was conducted on 48 children with VUR who underwent unilateral or bilateral RALUR-EV between June 2018 and December 2022. Patients were divided into two groups: Group A (25 infants under one year) and Group B (23 children over one year).
Research progress and treatment status of malignant ascites.
Front Oncol
December 2024
Department of Oncology, Guang'anmen Hospital Jinan Hospital (Jinan Hospital of Traditional Chinese Medicine), Jinan, China.
Malignant ascites (MA), a common and serious complication of various cancers in the abdominal cavity, originates from the extensive infiltration, metastasis, and growth of cancer cells in or on the abdominal cavity, leading to abnormal accumulation of fluid in the abdominal cavity and the formation of MA. MA seriously reduces the quality of life of cancer patients, shortens their survival period, and generally has a poor prognosis. Modern medicine has developed various strategies for the treatment of MA, including targeted supportive treatment, diuretic treatment, abdominal paracentesis, surgical intervention, and intraperitoneal administration therapy.
View Article and Find Full Text PDFRenal health benefits and therapeutic effects of parsley (): a review.
Front Med (Lausanne)
December 2024
Department of Internal Medicine, University of Jeddah, Jeddah, Saudi Arabia.
Parsley () has been used in traditional medicine for its diverse health benefits, and recent research highlights its potential in promoting renal health due to its bioactive compounds. This review focuses on evaluating the renal health benefits and therapeutic effects of parsley, addressing the growing interest in natural interventions for kidney-related conditions. It aims to consolidate existing evidence while identifying research gaps to support parsley's integration into renal health management.
View Article and Find Full Text PDFMedical and advanced heart failure therapies in Türkiye.
Turk J Med Sci
December 2024
Deputy Health Minister, Ministry of Health, Ankara, Turkiye.
Background/aim: Effective management of heart failure involves evidence-based use of multiple medications and their combinations. Furthermore, dosage escalation of the recommended medications is advised. In cases of advanced heart failure, long-term mechanical assistance devices or heart transplantation surgery may be necessary.
View Article and Find Full Text PDFDapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness.
BMC Cardiovasc Disord
December 2024
Department of Internal Medicine, AdventHealth Sebring, Sebring, FL, USA.
Article Synopsis
- Dapagliflozin is a promising treatment for Acute Heart Failure (AHF), showing benefits in reducing cardiovascular mortality and hospital readmissions compared to traditional therapies.
- A systematic review of five randomized controlled trials indicated that dapagliflozin significantly lowered in-hospital cardiovascular mortality rates and 30-day hospital readmissions without impacting hospital stay length or hypotension incidents.
- The research followed established protocols for data extraction and quality assessment, demonstrating a notable weight change in patients receiving dapagliflozin, reinforcing its efficacy as a treatment option in AHF.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!